Free tool
Stocks above their 200-day average
We cover 270 companies trading above their own 200-day average. The median market value in the group is $8.50B. Across the group, the median move over the past trading day is −0.05%. 100% of the 270 with a 200-day average trade above it. Price change over the past year runs from −4.3% to +206.6% across the middle 80 percent of the group, with a median of +32.8%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
270 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| ABTT34.SA | Abbott Laboratories | $199.23B | Large cap | −16.35% |
| ABT | Abbott Laboratories | $198.74B | Large cap | −11.83% |
| GILD | Gilead Sciences, Inc. | $184.47B | Large cap | +32.51% |
| GIS.DE | Gilead Sciences, Inc. | $184.35B | Large cap | +33.64% |
| PFE | Pfizer Inc. | $161.30B | Large cap | +18.72% |
| PFE.DE | Pfizer Inc. | $161.11B | Large cap | +22.96% |
| DHER34.SA | Danaher Corporation | $151.72B | Large cap | +0.89% |
| DAP.DE | Danaher Corporation | $151.59B | Large cap | +6.90% |
| DHR | Danaher Corporation | $151.40B | Large cap | +5.61% |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% |
| VRTX | Vertex Pharmaceuticals Incorporated | $138.63B | Large cap | +40.66% |
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% |
| BRM.DE | Bristol-Myers Squibb Company | $137.92B | Large cap | +50.84% |
| MDT | Medtronic plc | $117.78B | Large cap | +2.29% |
| 2M6.DE | Medtronic plc | $117.57B | Large cap | +2.65% |
| MCK | McKesson Corporation | $104.54B | Large cap | +31.57% |
| ELV | Elevance Health, Inc. | $87.30B | Large cap | +32.12% |
| E1LV34.SA | Elevance Health, Inc. | $86.53B | Large cap | +21.66% |
| REGN34.SA | Regeneron Pharmaceuticals, Inc. | $85.16B | Large cap | +33.80% |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.89B | Large cap | +39.36% |
| CI | The Cigna Group | $74.22B | Large cap | −4.84% |
| MRK.DE | Merck KGaA | $70.28B | Large cap | +32.17% |
| M1RN34.SA | Moderna, Inc. | $63.51B | Large cap | +462.13% |
| COR | Cencora, Inc. | $62.55B | Large cap | +13.45% |
| MRNA | Moderna, Inc. | $59.75B | Large cap | +496.25% |
| TAK | Takeda Pharmaceutical Company Limited | $58.60B | Large cap | +22.68% |
| 4502.T | Takeda Pharmaceutical Company Limited | $58.08B | Large cap | +36.03% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.25B | Large cap | +76.91% |
| BAY.WA | Bayer Aktiengesellschaft | $55.90B | Large cap | +76.59% |
| C1AH34.SA | Cardinal Health, Inc. | $55.77B | Large cap | +52.41% |
| CAH | Cardinal Health, Inc. | $55.45B | Large cap | +61.05% |
| EWL.DE | Edwards Lifesciences Corporation | $52.39B | Large cap | +11.65% |
| EW | Edwards Lifesciences Corporation | $52.32B | Large cap | +12.21% |
| SHL.DE | Siemens Healthineers AG | $51.23B | Large cap | −14.18% |
| HUM | Humana Inc. | $46.96B | Large cap | +33.14% |
| H1UM34.SA | Humana Inc. | $46.72B | Large cap | +24.36% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| H6D0.DE | Haleon plc | $44.85B | Large cap | +5.39% |
| HLN | Haleon plc | $44.72B | Large cap | +6.13% |
| HLN.L | Haleon plc | $44.62B | Large cap | +2.68% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.19B | Large cap | +110.08% |
| A | Agilent Technologies, Inc. | $43.80B | Large cap | +31.46% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| WAT | Waters Corporation | $40.67B | Large cap | +40.57% |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.39B | Large cap | +57.62% |
| VEE.DE | Veeva Systems Inc. | $40.02B | Large cap | +13.43% |
| VEEV | Veeva Systems Inc. | $39.78B | Large cap | −16.58% |
| RPRX | Royalty Pharma plc | $35.71B | Large cap | +74.00% |
| RMD | ResMed Inc. | $34.13B | Large cap | −15.77% |
| D1EX34.SA | DexCom, Inc. | $33.75B | Large cap | +9.64% |
| DXCM | DexCom, Inc. | $33.65B | Large cap | +16.47% |
| DC4.DE | DexCom, Inc. | $33.35B | Large cap | +21.06% |
| GEHC | GE HealthCare Technologies Inc. | $33.35B | Large cap | −1.15% |
| BIIB | Biogen Inc. | $32.66B | Large cap | +62.12% |
| C1NC34.SA | Centene Corporation | $32.65B | Large cap | +116.61% |
| IDP.DE | Biogen Inc. | $32.39B | Large cap | +65.32% |
| CNC | Centene Corporation | $32.34B | Large cap | +127.01% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.43B | Large cap | +1.64% |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% |
| MTD | Mettler-Toledo International Inc. | $28.10B | Large cap | +8.81% |
| MTO.DE | Mettler-Toledo International Inc. | $27.92B | Large cap | +13.15% |
| 4503.T | Astellas Pharma Inc. | $26.88B | Large cap | +53.57% |
| ROIV | Roivant Sciences Ltd. | $26.55B | Large cap | +206.51% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| WST | West Pharmaceutical Services, Inc. | $24.63B | Large cap | +42.61% |
| 4543.T | Terumo Corporation | $23.67B | Large cap | −2.68% |
| STE | STERIS plc | $23.09B | Large cap | −4.41% |
| GH | Guardant Health, Inc. | $22.94B | Large cap | +169.17% |
| THC | Tenet Healthcare Corporation | $21.89B | Large cap | +50.70% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $21.77B | Large cap | +11.32% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.68B | Large cap | +25.88% |
| VIA.DE | Viatris Inc. | $19.41B | Large cap | +67.32% |
| VTRS | Viatris Inc. | $19.35B | Large cap | +66.19% |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.34B | Large cap | −4.32% |
| MEDP | Medpace Holdings, Inc. | $17.28B | Large cap | +30.74% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | +100.35% |
| ASND | Ascendis Pharma A/S | $16.41B | Large cap | +29.66% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| NBIX | Neurocrine Biosciences, Inc. | $15.92B | Large cap | +13.36% |
| SOLV | Solventum Corporation | $15.58B | Large cap | +25.57% |
| SRT.DE | Sartorius Aktiengesellschaft | $15.54B | Large cap | +21.79% |
| BBIO | BridgeBio Pharma, Inc. | $15.52B | Large cap | +60.05% |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $15.44B | Large cap | +11.27% |
| ESF0.DE | Eurofins Scientific SE | $14.67B | Large cap | +12.65% |
| 7733.T | Olympus Corporation | $14.46B | Large cap | +27.06% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +42.93% |
| BAX | Baxter International Inc. | $13.70B | Large cap | +8.90% |
| PME.AX | Pro Medicus Limited | $13.66B | Large cap | −39.15% |
| B1AX34.SA | Baxter International Inc. | $13.60B | Large cap | +3.61% |
| ORNBV.HE | Orion Oyj | $13.16B | Large cap | +21.01% |
| ORNAV.HE | Orion Oyj | $13.11B | Large cap | +21.27% |
| ICLR | ICON Public Limited Company | $13.03B | Large cap | −2.91% |
| CORT | Corcept Therapeutics Incorporated | $12.95B | Large cap | +71.81% |
| PEN | Penumbra, Inc. | $12.72B | Large cap | +21.02% |
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% |
| FME.DE | Fresenius Medical Care AG | $12.64B | Large cap | −2.61% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% |
| ELAN | Elanco Animal Health Incorporated | $12.53B | Large cap | +35.64% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.52B | Large cap | +308.99% |
| FMS | Fresenius Medical Care AG | $12.51B | Large cap | −3.21% |
| R1VT34.SA | Revvity, Inc. | $12.50B | Large cap | +22.81% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.45B | Large cap | +26.78% |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | −6.49% |
| EHC | Encompass Health Corporation | $11.92B | Large cap | −1.75% |
| DVAI34.SA | DaVita Inc. | $11.70B | Large cap | +18.80% |
| DVA | DaVita Inc. | $11.41B | Large cap | +30.89% |
| TECH | Bio-Techne Corporation | $11.35B | Large cap | +29.33% |
| BTSG | BrightSpring Health Services, Inc. | $11.32B | Large cap | +156.37% |
| CYTK | Cytokinetics, Incorporated | $11.01B | Large cap | +109.36% |
| AXSM | Axsome Therapeutics, Inc. | $10.85B | Large cap | +69.99% |
| GKOS | Glaukos Corporation | $10.65B | Large cap | +89.83% |
| KRYS | Krystal Biotech, Inc. | $10.65B | Large cap | +143.67% |
| MOH | Molina Healthcare, Inc. | $10.57B | Large cap | +13.35% |
| PRAX | Praxis Precision Medicines, Inc. | $10.54B | Large cap | +704.28% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +197.09% |
| HSIC | Henry Schein, Inc. | $10.30B | Large cap | +31.02% |
| AVTR | Avantor, Inc. | $9.81B | Mid cap | +9.93% |
| PTGX | Protagonist Therapeutics, Inc. | $9.80B | Mid cap | +146.62% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| OSCR | Oscar Health, Inc. | $9.55B | Mid cap | +83.55% |
| TWST | Twist Bioscience Corporation | $9.41B | Mid cap | +451.89% |
| DEMANT.CO | Demant A/S | $9.36B | Mid cap | +17.12% |
| WDH1.DE | Demant A/S | $9.33B | Mid cap | −5.53% |
| KRK.WA | Krka, d. d. | $9.20B | Mid cap | +30.59% |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +99.97% |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −9.65% |
| HQY | HealthEquity, Inc. | $8.75B | Mid cap | +18.69% |
| BRKR | Bruker Corporation | $8.69B | Mid cap | +70.56% |
| ATR | AptarGroup, Inc. | $8.60B | Mid cap | −1.89% |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.51B | Mid cap | +4.01% |
| 4523.T | Eisai Co., Ltd. | $8.48B | Mid cap | +7.64% |
| TGTX | TG Therapeutics, Inc. Common Stock | $8.42B | Mid cap | +92.61% |
| ALKS | Alkermes plc | $8.25B | Mid cap | +68.07% |
| SYRE | Spyre Therapeutics, Inc. | $8.13B | Mid cap | +446.12% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +9.35% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +54.43% |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% |
| 6869.T | Sysmex Corporation | $7.28B | Mid cap | +3.66% |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +56.66% |
| CHE | Chemed Corporation | $7.11B | Mid cap | +20.79% |
| PACS | PACS Group, Inc. | $7.03B | Mid cap | +274.28% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% |
| HIMS | Hims & Hers Health, Inc. | $6.96B | Mid cap | −32.22% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% |
| 7747.T | Asahi Intecc Co., Ltd. | $6.68B | Mid cap | +53.99% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | +555.07% |
| HLUN-B.CO | H. Lundbeck A/S | $6.47B | Mid cap | +8.99% |
| 3088.T | MatsukiyoCocokara & Co. | $6.45B | Mid cap | −14.74% |
| BLTE | Belite Bio, Inc | $6.31B | Mid cap | +144.07% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +154.86% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.27B | Mid cap | +92.20% |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% |
| XENE | Xenon Pharmaceuticals Inc. | $6.18B | Mid cap | +64.11% |
| BLCO.TO | Bausch + Lomb Corporation | $6.18B | Mid cap | +19.34% |
| BLCO | Bausch + Lomb Corporation | $6.16B | Mid cap | +18.56% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +356.93% |
| STVN | Stevanato Group S.p.A. | $6.11B | Mid cap | −0.09% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +7.27% |
| CTEC.L | Convatec Group PLC | $6.01B | Mid cap | −1.95% |
| T1FX34.SA | Teleflex Incorporated | $6.00B | Mid cap | +0.29% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +31.96% |
| DFTX | Definium Therapeutics, Inc. | $5.88B | Mid cap | +344.37% |
| TFX | Teleflex Incorporated | $5.88B | Mid cap | +8.06% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.74B | Mid cap | +80.92% |
| CRSP | CRISPR Therapeutics AG | $5.73B | Mid cap | +10.65% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% |
| SHC | Sotera Health Company | $5.58B | Mid cap | +18.42% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | −0.28% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | +11.33% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +207.13% |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +121.31% |
| 128940.KS | Hanmi Pharm. Co., Ltd. | $4.63B | Mid cap | +66.34% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.61B | Mid cap | −9.62% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% |
| ICUI | ICU Medical, Inc. | $4.49B | Mid cap | +41.83% |
| NVST | Envista Holdings Corporation | $4.47B | Mid cap | +30.89% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +50.93% |
| LIVN | LivaNova PLC | $4.41B | Mid cap | +41.56% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| INDV | Indivior Pharmaceuticals, Inc. | $4.23B | Mid cap | +47.06% |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.08B | Mid cap | +1.26% |
| VKTX | Viking Therapeutics, Inc. | $4.01B | Mid cap | +29.15% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +57.50% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% |
| MCOV-B.ST | Medicover AB (publ) | $3.85B | Mid cap | −8.20% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.82B | Mid cap | +4.88% |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −8.02% |
| 4536.T | Santen Pharmaceutical Co., Ltd. | $3.74B | Mid cap | +21.45% |
| 7459.T | MediPal Holdings Corporation | $3.72B | Mid cap | +13.38% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% |
| QURE | uniQure N.V. | $3.53B | Mid cap | +223.49% |
| NHC | National HealthCare Corporation | $3.53B | Mid cap | +103.83% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| MBX | MBX Biosciences, Inc. | $3.22B | Mid cap | +366.53% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +79.06% |
| AFX.DE | Carl Zeiss Meditec AG | $3.19B | Mid cap | −24.83% |
| CLDX | Celldex Therapeutics, Inc. | $3.19B | Mid cap | +79.51% |
| IRON | Disc Medicine, Inc. | $3.17B | Mid cap | +37.90% |
| WRBY | Warby Parker Inc. | $3.15B | Mid cap | −3.96% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.10B | Mid cap | +22.19% |
| ALMS | Alumis Inc. | $3.06B | Mid cap | +380.08% |
| BIOA-B.ST | BioArctic AB (publ) | $3.00B | Mid cap | +12.31% |
| ACHC | Acadia Healthcare Company, Inc. | $2.85B | Mid cap | +37.81% |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| VRDN | Viridian Therapeutics, Inc. | $2.75B | Mid cap | +30.71% |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +219.58% |
| PGEN | Precigen, Inc. | $2.65B | Mid cap | +61.66% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −12.10% |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% |
| BHVN | Biohaven Ltd. | $2.56B | Mid cap | +8.65% |
| TRVI | Trevi Therapeutics, Inc. | $2.55B | Mid cap | +124.00% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +151.95% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +15.38% |
| CURA.TO | Curaleaf Holdings, Inc. | $2.51B | Mid cap | +197.74% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +321.09% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.44B | Mid cap | +5.23% |
| BHC | Bausch Health Companies Inc. | $2.43B | Mid cap | −10.45% |
| BHC.TO | Bausch Health Companies Inc. | $2.43B | Mid cap | −9.88% |
| OCUL | Ocular Therapeutix, Inc. | $2.37B | Mid cap | −12.58% |
| GRDN | Guardian Pharmacy Services, Inc. | $2.36B | Mid cap | +45.50% |
| 009420.KS | Hanall Biopharma Co., Ltd. | $2.36B | Mid cap | +112.62% |
| UFPT | UFP Technologies, Inc. | $2.36B | Mid cap | +41.94% |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +27.27% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | Mid cap | +4.23% |
| BFLY | Butterfly Network, Inc. | $2.30B | Mid cap | +450.32% |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% |
| CLOV | Clover Health Investments, Corp. | $2.26B | Mid cap | +57.99% |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | +1.03% |
| ADUS | Addus HomeCare Corporation | $2.25B | Mid cap | +4.50% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | +36.58% |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +56.87% |
| EXE.TO | Extendicare Inc. | $2.18B | Mid cap | +146.56% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | +97.73% |
| CLOV34.SA | Clover Health Investments, Corp. | $2.15B | Mid cap | +45.23% |
| STOK | Stoke Therapeutics, Inc. | $2.14B | Mid cap | +71.45% |
| 008930.KS | Hanmi Science Co., Ltd. | $2.11B | Mid cap | +2.80% |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% |
| SRPT | Sarepta Therapeutics, Inc. | $2.06B | Mid cap | +7.69% |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% |
| SEM | Select Medical Holdings Corp | $2.05B | Mid cap | +28.14% |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $2.03B | Mid cap | −13.45% |
| CMPS | COMPASS Pathways plc | $2.02B | Mid cap | +209.53% |
| 6960.T | Fukuda Denshi Co., Ltd. | $2.02B | Mid cap | +79.12% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.